Tags

Type your tag names separated by a space and hit enter

Agalsidase alfa slows the decline in renal function in patients with Fabry disease.
Am J Nephrol. 2009; 29(5):353-61.AJ

Abstract

The aim of this study was to determine the effects of enzyme replacement therapy with agalsidase alpha on renal function in patients with Fabry nephropathy. Serum creatinine data were collected from 165 adult patients during 3 years of treatment. Serum creatinine increased in all men whereas it was stable in women, except in stage II renal disease (Kidney Disease Outcomes Quality Initiative). The estimated glomerular filtration rate (eGFR) declined in males with stage I and II (from 115.0 +/- 22.2 to 98.3 +/- 27.3 and from 76.5 +/- 8.1 to 66.3 +/-21.6 ml/min/1.73 m(2), respectively; both p < 0.01), whereas eGFR was stable in stage III. In females, eGFR was stable in stages I and III, and decreased in stage II (from 72.5 +/- 8.3 to 67.3 +/- 13.6 ml/min/1.73 m(2); p = 0.01). The 24-hour proteinuria was <1 g in all patients, and most patients (96%) were treated with angiotensin receptor blockers (ARBs) or angiotensin-converting enzyme (ACE) inhibitors. Agalsidase alpha in combination with ACE inhibitors/ARB may be effective in slowing the deterioration in renal function in Fabry nephropathy.

Authors+Show Affiliations

Nephrology and Dialysis, Belcolle Hospital, Strada Sammartinese snc, Viterbo, Italy. sandro.feriozzi@tiscali.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

18974635

Citation

Feriozzi, Sandro, et al. "Agalsidase Alfa Slows the Decline in Renal Function in Patients With Fabry Disease." American Journal of Nephrology, vol. 29, no. 5, 2009, pp. 353-61.
Feriozzi S, Schwarting A, Sunder-Plassmann G, et al. Agalsidase alfa slows the decline in renal function in patients with Fabry disease. Am J Nephrol. 2009;29(5):353-61.
Feriozzi, S., Schwarting, A., Sunder-Plassmann, G., West, M., & Cybulla, M. (2009). Agalsidase alfa slows the decline in renal function in patients with Fabry disease. American Journal of Nephrology, 29(5), 353-61. https://doi.org/10.1159/000168482
Feriozzi S, et al. Agalsidase Alfa Slows the Decline in Renal Function in Patients With Fabry Disease. Am J Nephrol. 2009;29(5):353-61. PubMed PMID: 18974635.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Agalsidase alfa slows the decline in renal function in patients with Fabry disease. AU - Feriozzi,Sandro, AU - Schwarting,Andreas, AU - Sunder-Plassmann,Gere, AU - West,Michael, AU - Cybulla,Markus, AU - ,, Y1 - 2008/10/31/ PY - 2008/04/24/received PY - 2008/09/03/accepted PY - 2008/11/1/pubmed PY - 2009/8/6/medline PY - 2008/11/1/entrez SP - 353 EP - 61 JF - American journal of nephrology JO - Am J Nephrol VL - 29 IS - 5 N2 - The aim of this study was to determine the effects of enzyme replacement therapy with agalsidase alpha on renal function in patients with Fabry nephropathy. Serum creatinine data were collected from 165 adult patients during 3 years of treatment. Serum creatinine increased in all men whereas it was stable in women, except in stage II renal disease (Kidney Disease Outcomes Quality Initiative). The estimated glomerular filtration rate (eGFR) declined in males with stage I and II (from 115.0 +/- 22.2 to 98.3 +/- 27.3 and from 76.5 +/- 8.1 to 66.3 +/-21.6 ml/min/1.73 m(2), respectively; both p < 0.01), whereas eGFR was stable in stage III. In females, eGFR was stable in stages I and III, and decreased in stage II (from 72.5 +/- 8.3 to 67.3 +/- 13.6 ml/min/1.73 m(2); p = 0.01). The 24-hour proteinuria was <1 g in all patients, and most patients (96%) were treated with angiotensin receptor blockers (ARBs) or angiotensin-converting enzyme (ACE) inhibitors. Agalsidase alpha in combination with ACE inhibitors/ARB may be effective in slowing the deterioration in renal function in Fabry nephropathy. SN - 1421-9670 UR - https://www.unboundmedicine.com/medline/citation/18974635/Agalsidase_alfa_slows_the_decline_in_renal_function_in_patients_with_Fabry_disease_ L2 - https://www.karger.com?DOI=10.1159/000168482 DB - PRIME DP - Unbound Medicine ER -